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Abstract
The primary risk factor for atherosclerotic cardiovascular disease is LDL cholesterol, which can be reduced by increasing
cholesterol excretion from the body. Fecal cholesterol excretion can be driven by a hepatobiliary as well as a non-biliary
pathway known as transintestinal cholesterol efflux (TICE). We previously showed that chronic knockdown of the hepatic
cholesterol esterifying enzyme sterol O-acyltransferase 2 (SOAT2) increased fecal cholesterol loss via TICE. To elucidate the
initial events that stimulate TICE, C57Bl/6 mice were fed a high cholesterol diet to induce hepatic cholesterol accumulation
and were then treated for 1 or 2 weeks with an antisense oligonucleotide targeting SOAT2. Within 2 weeks of hepatic
SOAT2 knockdown (SOAT2HKD), the concentration of cholesteryl ester in the liver was reduced by 70% without a reciprocal
increase in hepatic free cholesterol. The rapid mobilization of hepatic cholesterol stores resulted in a ,2-fold increase in
fecal neutral sterol loss but no change in biliary cholesterol concentration. Acute SOAT2HKD increased plasma cholesterol
carried primarily in lipoproteins enriched in apoB and apoE. Collectively, our data suggest that acutely reducing SOAT2
causes hepatic cholesterol to be swiftly mobilized and packaged onto nascent lipoproteins that feed cholesterol into the
TICE pathway for fecal excretion.
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Introduction
Despite advances in treatment and prevention, cardiovascular
disease remains the number one killer of Americans [1]. High
blood concentrations of LDL cholesterol (LDLc) lead to the
development of atherosclerosis, which is the principal cause of the
majority of clinical cardiovascular events [1]. By inhibiting
cholesterol synthesis and consequently increasing LDL clearance
from the blood, statins have the ability to significantly reduce
LDLc and have been shown to reduce the risk of cardiovascular
disease by as much as 44% [2]. However, statin treatment is not
always effective at lowering LDLc to the recommended target level
and can cause side effects such as myopathy and elevated liver
enzymes [3]. Therefore, it is important to develop other
treatments that will reduce LDLc or modulate LDL atherogenic-
ity. A promising treatment option is the inhibition of sterol O-acyl
transferase 2 (SOAT2) also termed acyl-CoA:cholesterol O-acyl
transferase 2 (ACAT2). SOAT2 is a transmembrane-associated
enzyme localized to the endoplasmic reticulum of hepatocytes and
enterocytes and catalyzes the transfer of the fatty acid from long
chain acyl CoA to the 39 hydroxyl group of cholesterol [4,5]. The
cholesteryl esters (CE) produced by SOAT2 can be packaged into
nascent, apoB-containing chylomicrons and VLDL or stored in
cytosolic neutral lipid droplets [6]. We have previously shown that
in vitro a systematic increase in SOAT2 expression resulted in
increased CE secretion in apoB-containing lipoproteins [7]. Mice
with whole-body or intestine-specific knockout of Soat2 have
reduced cholesterol absorption [8–10] due to an inability to
efficiently package cholesterol as CE into chylomicrons [11].
Deficiency of Soat2 in liver results in the secretion of VLDL that
are depleted of CE [12] thus resulting in a significant reduction in
plasma VLDLc concentration [10,13–16]. Mice with whole-body
or liver-specific disruption of Soat2 often do not display a change
in plasma LDLc [10,14,17] because of the ability of lecithin-
cholesterol acyltransferase (LCAT) to form CE on plasma LDL
[12,14,18]. However, regardless of plasma LDLc concentration,
Soat2 deficiency significantly reduces atherosclerosis development
in Ldlr-/- and Apoe-/- mice [13–15,17]. The reduced atheroge-
nicity of LDL from Soat2 deficient mice appears to be caused in
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part by SOAT2-derived cholesteryl oleate depletion that decreases
LDL binding to proteoglycans [13].
Similar to targeted gene deletion, inhibition of function or
disruption of expression of SOAT2 by pharmacological means
causes major alterations in cholesterol homeostasis and athero-
sclerosis development. Treatment of Apoe-/- mice with the
SOAT2 selective inhibitor pyripyropene A caused reductions in
cholesterol absorption, plasma VLDLc and LDLc concentration,
cholesteryl oleate content of apoB-containing lipoproteins, and
atherosclerosis progression [19]. By using an antisense oligonu-
cleotide targeting Soat2 mRNA (SOAT2 ASO), SOAT2 expres-
sion was knocked down in a liver-specific manner resulting in
decreased LDL cholesteryl oleate and diminished aortic athero-
sclerosis development [20].
It was anticipated that hepatic SOAT2 knockdown
(SOAT2HKD) would cause free cholesterol (FC) to accumulate in
the liver since cholesterol absorption would be normal but the
hepatocytes would be unable to esterify any excess cholesterol
delivered by chylomicrons. In spite of unaltered cholesterol
absorption and a near absence of SOAT2 expression and activity
in liver, hepatic FC concentration was normal in apoB100 only,
Ldlr-/- mice with SOAT2HKD [21]. To presumably protect the
liver from FC toxicity, there was a 2-fold increase in fecal
cholesterol excretion in SOAT2HKD mice. Since mice treated with
SOAT2 ASO had no change in biliary cholesterol secretion and
normal cholesterol absorption, we hypothesized that the increased
fecal cholesterol excretion was the result of increased transintest-
inal cholesterol efflux (TICE), a process by which cholesterol is
secreted into the lumen of the small intestine after being delivered
through plasma to the enterocytes [22,23]. To determine whether
the liver of SOAT2 ASO-treated mice was producing a lipoprotein
that was preferentially targeted for clearance by the small intestine,
isolated liver perfusion was conducted on mice that had been
radiolabeled with [3H]cholesterol and treated with control or
SOAT2 ASO. The radiolabeled perfusate, which carried almost
100% of the cholesterol on VLDL, was then injected into control
and SOAT2 ASO treated mice. After 6 hr, 2–3 fold more
[3H]cholesterol from the SOAT2HKD perfusate compared to the
control perfusate had accumulated in the lumen and wall of the
proximal small intestine. From this result we concluded that the
VLDL secreted from the SOAT2HKD liver was preferentially
targeted to the small intestine [21].
In the current study, we wanted to determine the initial changes
that occur in cholesterol metabolism when SOAT2 expression is
knocked down in liver. To increase the likelihood of stimulating
cholesterol excretion via the hepatobiliary and/or TICE path-
ways, C57BL/6 mice were fed a high cholesterol diet (0.2%; wt/
wt) for 6 weeks to induce hepatic CE accumulation. After hepatic
cholesterol loading, the mice were treated with control or SOAT2
ASO for 1–2 weeks. Acute treatment with SOAT2 ASO rapidly
reduced hepatic SOAT2 expression and CE concentration but
had no significant impact on FC in the liver. Similar to chronic
SOAT2HKD, acute SOAT2HKD did not alter biliary cholesterol
concentration but almost doubled fecal cholesterol excretion
therefore indicating that the TICE pathway was stimulated. The
increased plasma concentration of FC, apoB, and apoE suggests
that the liver of SOAT2HKD may be producing lipoproteins that
preferentially feed cholesterol into the TICE pathway.
Materials and Methods
Mice
Female C57BL/6N wild-type mice were maintained on
standard rodent diet. At 6–8 weeks of age, the mice were switched
to a semisynthetic low-fat, high-cholesterol diet (10% of energy as
palm oil-enriched fat, 0.2% cholesterol w/w) and maintained on
this diet for the remainder of the study. After 6 weeks of high-
cholesterol diet feeding, mice were injected intraperitoneally
biweekly with 25 mg/kg of either non-targeting ASO (Control
ASO-ISIS 353512 (59-TCCCATTTCAGGAGACCTGG-39) [24]
or ASO directed against murine SOAT2 (SOAT2 ASO-ISIS
217006 (59-TTCGGAAATGTTGCACCTCC-39), as previously
described [20,21,24]. After 1 or 2 weeks of treatment, mice were
fasted for 4 hr and anesthetized with ketamine/xylazine (120/
20 mg/kg, intramuscular injection). Bile was collected from the
gallbladder. Blood was collected by heart puncture, and euthana-
sia was achieved by exanguination. Following a whole body flush
with saline, the liver and small intestine were collected and snap
frozen in liquid nitrogen. All mice were maintained in an
American Association for Accreditation of Laboratory Animal
Care-approved animal facility under protocols approved by the
Institutional Animal Care and Use Committee at Wake Forest
University School of Medicine.
Immunoblotting of Tissue Proteins and Lipoprotein
Apolipoproteins
Liver microsomes were prepared as previously described [25].
Briefly, liver samples were homogenized in SOAT2 homogeniza-
tion buffer (0.25 M sucrose, 1 mM EDTA, 0.1 M K2HPO4) in the
presence of protease inhibitor cocktail (Sigma) and then centri-
fuged to remove cellular debris. The supernatant was centrifuged
with added protease inhibitor at 100,0006g for 1 hour to isolate
the microsomal fraction. Western blots of whole liver lysates for
ABCA1, TGH1, and liver microsomes for SOAT2 were
conducted as previously described [21,24]. For apolipoprotein
analysis, an equal volume of plasma from each mouse within a
treatment group was pooled. 200 mL of pooled plasma for groups
treated with diet only, SOAT2 ASO for 1 week, SOAT2 ASO for
2 weeks and control ASO for 2 weeks and 150 mL of pooled
plasma for the group treated with control ASO for 1 week were
separated on a Superose 6 10/300 GL column (GE Healthcare) at
a flow rate of 0.4 ml/min and fractions were collected at defined
intervals. An equal volume within lipoprotein fractions from the
groups diet only, SOAT2 ASO for 1 week, SOAT2 ASO for 2
weeks and control ASO for 2 weeks and 25% more volume of the
fractions from the group treated with control ASO for 1 week were
mixed with 5X SDS sample buffer and separated on a NuPAGE
Novex 4–12% Bis Tris Midi Gel using 1X NuPAGE MOPS SDS
running buffer (Invitrogen). The proteins were transferred to a
nitrocellulose membrane, which was subsequently blocked with
5% (w/v) non-fat dried milk dissolved in wash buffer. The
membrane was incubated overnight at 4uC with one or more of
the following antibodies: rabbit anti-human apoAI (Biodesign),
goat polyclonal to human apoB (Academy Biomedical) or rabbit
polyclonal to rat apoE (provided by Dr. Joachim Herz, UT
Southwestern Medical Center). After washing, the blots were
exposed to secondary antibodies against goat or rabbit IgG
conjugated to horseradish peroxidase (Sigma), and the probed
proteins were visualized with ECL reagent (PerkinElmer) and
exposure to Blue X-Ray Film (Phenix).
Quantitative Real-Time PCR (qPCR)
RNA extraction and qPCR were conducted as previously
described on individual tissue samples (n = 5 per group) [8].
Cyclophilin was used as an internal control, and mRNA
expression levels were calculated based on DD-CT method.
Messenger RNA levels for each gene represent the amount
relative to that of WT mice treated with control ASO, which was
Acutely Reducing Hepatic SOAT2 Raises Cholesterol Excretion
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arbitrarily standardized to 1. Primer sequences used for qPCR are
available on request.
Plasma Concentration and Distribution of Cholesterol
Plasma total cholesterol concentration and lipoprotein choles-
terol distributions were determined as described previously [26].
Plasma free cholesterol concentration was determined using the
Free Cholesterol E reagent (Wako). For determination of the free
cholesterol to total cholesterol ratio (FC/TC) in lipoprotein classes,
an equal volume of plasma from each mouse within a treatment
group was pooled. 200 mL of pooled plasma for the groups treated
with diet only, SOAT2 ASO for 1 week, SOAT2 ASO for 2 weeks
and control ASO for 2 weeks and 150 mL of pooled plasma for the
group treated with control ASO for 1 week were separated on a
Superose 6 10/300 GL column (GE Healthcare) at a flow rate of
0.4 ml/min and fractions were collected at defined intervals. A
known volume of each interval was Bligh-Dyer extracted in tubes
containing 5-alpha cholestane as an internal standard [27]. Once
the collected chloroform was dried down the extract was re-
suspended in hexane and analyzed by gas chromatography (GC)
[7]. After analysis for free cholesterol concentration the hexane
was collected and dried down so the extract could be saponified for
total cholesterol analysis by GC.
Liver and Gallbladder Lipid Measurements
Lipid concentrations in the liver and the gallbladder bile were
determined as described previously [8,28,29].
Analysis of Fecal Neutral Sterol Excretion
Immediately following the first ASO injection, mice were
individually housed in wire bottom cages to collect feces for
neutral sterol analysis. After 72 hr, the mice were administered a
second dose of the respective ASO and transferred to clean wire
bottom cages for a second collection of feces. After 96 hr in this
setting, the mice were fasted for 4 hr, euthanized, and bile,
plasma, liver, and small intestine were collected for analysis. A
second set of mice received their first week of ASO doses in normal
caging. After their third ASO dose, the mice were individually
housed in wire bottom cages and feces were collected for 72 hr.
These mice then received another ASO dose and were transferred
to a clean wire bottom cages in order to collect feces for 96 hr.
Tissue and fluid samples were then collected from these mice as
described above. Fecal neutral sterol excretion was measured as
described previously [8].
Statistical Analysis
Data are expressed as the mean 6 standard error of the mean
(SEM) and were analyzed using multivariate analysis of variance
(ANOVA), followed by Student’s t tests for post hoc analysis.
Differences were considered significant at p,0.05. All analyses
were performed using JMP version 5.0.12 (SAS Institute; Cary,
NC) software, unless otherwise specified.
Results
SOAT2 knockdown rapidly reduces hepatic cholesteryl
ester stores
Female C57BL/6N wild-type mice were fed a high-cholesterol
diet (0.2% w/w) for 6 weeks to induce hepatic cholesteryl ester
(CE) accumulation, and were then treated for 1 or 2 weeks with
either control ASO or an ASO targeting SOAT2. Within 1 week
of administration of SOAT2 ASO versus control ASO, hepatic
SOAT2 mRNA was reduced by .85% (Figure 1A). SOAT2 ASO
treatment did not significantly alter intestinal SOAT2 mRNA
expression (Figure 1B). Knockdown of SOAT2 mRNA for 1 week
reduced hepatic SOAT2 protein by 67% (Figure 1C) and hepatic
CE by 55% (Figure 1D). SOAT2 protein and CE in liver were
decreased by 80% and 72%, respectively, in mice treated for 2
weeks with SOAT2 ASO compared to control ASO. Hepatic free
cholesterol (FC) was not significantly different in mice adminis-
tered SOAT2 ASO versus control ASO for 1 or 2 weeks
(Figure 1E). However, there was a 60% reduction in hepatic FC in
mice treated with SOAT2 ASO for 2 weeks versus 1 week
(Figure 1E).
Acute hepatic SOAT2 knockdown increases fecal
cholesterol excretion in mice without altering biliary
lipids
We next investigated whether the rapid and dramatic reduction
in CE caused by hepatic SOAT2 knockdown (SOAT2HKD)
resulted in increased cholesterol movement into the bile. When
biliary lipid levels of gallbladder bile were measured, biliary
cholesterol concentration (Figure 2A) was not significantly
increased in mice treated with SOAT2 ASO compared with
control ASO or diet alone. In contrast, mice dosed with SOAT2
ASO for 2 weeks versus 1 week did display a significant 36%
decrease in biliary cholesterol concentration (Figure 2A). To
normalize for differences caused by the bile being concentrated
while stored in the gallbladder, the molar ratio of cholesterol in
bile was calculated. Acute SOAT2HKD had almost identical
qualitative effects on the molar ratio (Figure 2B) and concentration
(Figure 2A) of cholesterol in bile. Excess cholesterol can also be
eliminated from the liver by conversion into bile acids. However,
similar to cholesterol, SOAT2HKD did not increase bile acid
concentration (Figure 2C) or molar ratio (Figure 2D). Biliary
phospholipids solubilize newly secreted biliary cholesterol; yet,
biliary phospholipid concentration (Figure 2E) and molar ratio
(Figure 2F) also were unchanged upon SOAT2HKD. Although
there were no major alterations in biliary lipids when hepatic CE
was rapidly depleted, fecal neutral sterol excretion was increased
92% within 72 hr of the first SOAT2 ASO injection (Figure 3).
With the exception of the 96 hr period following the second ASO
injection (Day 4-7), output of neutral sterol into the feces was
significantly greater at each time point in mice treated with
SOAT2 ASO compared to control ASO (Figure 3).
Acute hepatic SOAT2 knockdown transiently increases
plasma total cholesterol and doubles plasma free
cholesterol
Plasma total cholesterol (TC) (Figure 4A) and plasma FC
(Figure 4B) were both significantly increased after one week of
SOAT2HKD, suggesting that a proportion of the hepatic CE stores
was rapidly secreted into the plasma. After 2 weeks of treatment,
plasma concentrations of TC and FC were no longer different
between mice receiving SOAT2 ASO and control ASO. In order
to determine which lipoprotein classes were being impacted by
acute SOAT2HKD, TC distribution on plasma lipoproteins was
measured. As observed previously [21], VLDL-TC was reduced
upon hepatic SOAT2 knockdown (Figure 4C). SOAT2 ASO
treatment for 1 and 2 weeks increased TC in LDL and small
LDL/large HDL, which are referred to in this work as transition
lipoproteins (TL). This ‘‘transition’’ lipoprotein simply refers to the
fact that these lipoproteins elute between the canonical LDL and
HDL peaks following size exclusion chromatography. HDL-TC
was similar for mice treated with SOAT2 ASO compared to
control ASO for either 1 or 2 weeks (Figure 4C). However,
Acutely Reducing Hepatic SOAT2 Raises Cholesterol Excretion
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SOAT2HKD for 2 weeks compared to 1 week appeared to
substantially decrease HDL-TC (Figure 4C). To define the
lipoprotein classes enriched in FC, VLDL, LDL, TL, and HDL
was isolated from plasma using gel filtration chromatography
(Figure 4C) and the ratio of FC to TC in the fractions was
determined. SOAT2HKD appeared to increase the FC to TC ratio
in all of the lipoprotein classes at both times of observation, but
this ratio was most prominently increased in the VLDL and TL
fractions (Figure 4D).
Apolipoprotein content of plasma lipoproteins following
acute hepatic SOAT2 knockdown
Analysis of the relative apolipoprotein abundance in the VLDL,
LDL, TL, and HDL fractions showed the major apolipoprotein
species present among the lipoprotein fractions. Compared to
mice receiving control ASO, mice with SOAT2HKD had a
reduction in apoB100 and apoB48 in VLDL (Figure 5A). By
contrast, apoB100 abundance was increased in the LDL
(Figure 5B) and TL (Figure 5C) fractions of mice treated for 1
and 2 weeks with SOAT2 ASO versus control ASO. Similar to
other murine models where TICE appears to be increased [30],
mice with acute hepatic SOAT2 knockdown had increased apoE
abundance in TL and HDL (Figure 5C and 5D). Consistent with
the relatively stable HDL-TC concentrations, apoAI abundance in
HDL was similar among the different treatment groups.
Hepatic expression of genes involved in cholesterol
homeostasis in mice with acute knockdown of SOAT2
Although FC concentrations were unchanged when comparing
mice treated with SOAT2 ASO and control ASO (Figure 1E), it
Figure 1. Hepatic SOAT2 knockdown rapidly reduces cholesteryl ester levels in liver. After consuming a high cholesterol diet for 6 weeks,
mice were either euthanized to collect baseline samples or were continued on diet and administered for 1 or 2 weeks control ASO or SOAT2 ASO.
Quantitation of SOAT2 mRNA in liver (A) and proximal third of small intestine (B) were conducted by real-time PCR using individual RNA samples
(n = 5 per treatment group). (C) Western blot analysis was used to detect hepatic SOAT2 protein expression in liver microsomes. To compare the
relative expression of SOAT2 between treatment groups, the band intensity of SOAT2 was normalized to that of calnexin and quantification of
protein levels was determined by densitometry (C). Fasting livers were collected and analyzed for the concentration of cholesteryl ester (CE) (D) and
free cholesterol (FC) (E). All hepatic lipid values were normalized to the protein content of the extracted tissue, and represent the means 6 SEM (4–6
mice per treatment group). Bars not sharing a common letter differ significantly (p,0.05).
doi:10.1371/journal.pone.0098953.g001
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was possible that acute SOAT2HKD was increasing a regulatory
pool of FC that was inactivating sterol response binding element
protein 2 (SREBP2) or stimulating liver X receptor (LXR) thus
altering hepatic expression of genes involved in cholesterol
homeostasis. A reduction in cholesterol synthesis could potentially
compensate for an increase in FC caused by hepatic SOAT2
depletion. However, the mRNA abundance of HMG-CoA
synthase, HMG-CoA reductase, and SREBP2 were not altered
in mice treated with the SOAT2 ASO for 1 or 2 weeks (Figure 6A-
C). By upregulating the expression of the LXR target genes
ABCG5, ABCG8 and ATP binding cassette transporter A1
(ABCA1), excess FC could have been effluxed from the livers of
SOAT2HKD mice to bile or HDL, respectively. However, unlike
our previous study with chronic SOAT2HKD [21], hepatic ABCA1
protein did not appear to increase with acute SOAT2HKD
(Figure 6D). SOAT2 ASO treatment did not alter the hepatic
expression of ABCG5 mRNA (Figure 6E) but did slightly increase
hepatic ABCG8 mRNA (Figure 6F). Furthermore, the hepatic
mRNA expression of the HDL receptor SR-BI was unchanged by
SOAT2 ASO treatment (Figure 6G). Interestingly, an enzyme that
has been shown to hydrolyze triglyceride and cholesteryl ester,
triglyceride hydrolase 1 (TGH1), was slightly increased at both the
mRNA and protein level with SOAT2 ASO treatment (Figure 6H-
I) [31].
Figure 2. Impact of acute hepatic SOAT2 knockdown on the concentration and molar ratio of lipids in gallbladder bile. Mice were
treated as described in the legend for Figure 1. Gallbladder bile was collected and analyzed for the concentration of cholesterol (A), bile acids (B), and
phospholipids (C). To calculate the molar ratio of cholesterol (D), bile acids (E), and phospholipids (F), the concentration of each biliary lipid was
divided by the sum of the concentrations of the three biliary lipids. Data represent the means 6 SEM (n = 5–6 mice per treatment group). Bars not
sharing a common letter differ significantly (p,0.05).
doi:10.1371/journal.pone.0098953.g002
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Intestinal expression of genes involved in cholesterol
metabolism are not altered by SOAT2 ASO treatment
Given that SOAT2 ASO treatment promotes rapid flux of liver-
derived cholesterol to the small intestine, we interrogated the
expression of genes involved in cholesterol metabolism in the
proximal small intestine where TICE is most active. Interestingly,
SOAT2 ASO treatment failed to alter the expression of SOAT2,
SR-BI, ABCG5, ABCG8, NPC1L1, or TGH1. These results
suggest that SOAT2 ASO treatment has divergent effects on gene
expression in the liver (Figure 6) and small intestine (Figure 7).
Discussion
Chronic hepatic knockdown of SOAT2 expression appears to
stimulate TICE resulting in increased cholesterol excretion and
decreased LDLc concentration [21]. In the current study, we
sought to determine the initial changes that occur in cholesterol
homeostasis when SOAT2 expression is knocked down in liver. In
mice that had been previously fed a high-cholesterol diet to induce
hepatic CE accumulation, treatment with SOAT2 ASO for 1-2
weeks caused 1) knockdown of hepatic SOAT2 expression and
consequently rapid depletion of CE from the liver, 2) increased
plasma FC carried on apoB- and apoE-containing lipoproteins
and 3) elevated fecal neutral sterol excretion without major
perturbations in biliary cholesterol. Since our current results are
consistent with those caused by chronic SOAT2 knockdown [21],
we conclude that cholesterol liberated from the liver due to acute
hepatic SOAT2 knockdown is rapidly mobilized onto lipoproteins
that feed into the TICE pathway.
Acute treatment with SOAT2 ASO caused a rapid and
dramatic reduction in hepatic SOAT2 expression (Figure 1A
and 1C) and a concomitant breakdown of CE stores in the liver
(Figure 1D). It is reasonable to assume that upon SOATHKD in
cholesterol-fed mice, the hepatic cholesterol esterification and
hydrolysis cycle was unbalanced resulting in rapid turnover of
stored CE. Neutral lipid hydrolases such as TGH-1/CES3, HSL,
and neutral cholesteryl ester hydrolase may have been responsible
for the breakdown of CE (Figure 6H–I) [31,32]. In particular, the
hepatic expression of TGH1 was stimulated slightly by SOAT2
ASO treatment (Figure 6H–I). It is also possible that the rapid
depletion of hepatic CE was driven by autophagy, which has been
shown to play a major role in CE turnover in macrophage foam
cells [33,34].
Although consistent with our previous studies of SOAT2
knockdown and knockout in the liver [10,21], it was quite
surprising that hepatic FC concentration was not significantly
altered in mice acutely treated with SOAT2 ASO versus control
ASO (Figure 1D). The absorption of cholesterol should have been
normal in SOATHKD mice [21] resulting in the delivery of
cholesterol-rich chylomicron remnants to the liver. The majority
of the cholesterol coming from the chylomicron remnants and
other plasma lipoproteins should have remained unesterified in
hepatocytes with SOAT2 knockdown. Moreover, the livers of
SOATHKD mice faced the additional burden of FC originating
from the rapid turnover of CE in the intracellular lipid droplets.
Nevertheless, hepatocytes with SOAT2 knockdown were able to
adapt to the new sources of FC and maintain cellular FC at a
proper level. Reducing cholesterol synthesis in the liver could have
offset the increase in hepatic FC caused by acute SOAT2
knockdown. However, mRNA expression of the master transcrip-
tional regulator of cholesterol biosynthesis Srebf2 and its target
genes HMGCoA reductase and HMGCoA synthase were not
changed in mice treated acutely with SOAT2 ASO (Figure 6A–C).
Excess FC could have also been eliminated from the liver by
secretion directly into bile or conversion to bile acids. Yet acute
treatment with SOAT2 ASO compared to control ASO did not
significantly alter the concentration of cholesterol (Figure 2A) and
bile acids (Figure 2B) in gallbladder bile. Like our previous findings
that gallbladder cholesterol and bile acid levels were unaltered in
mice with chronic SOATHKD [21], our current results indicate
that acute knockdown of SOAT2 in liver does not drive FC
towards secretion into bile or conversion into bile acids. However,
since biliary lipids were only measured in gallbladder bile collected
after 1 and 2 weeks of SOAT2 ASO treatment, it is possible that
biliary secretion of cholesterol and bile acids was significantly
increased prior to our two time points for gallbladder bile
sampling.
Based upon the finding that fecal neutral sterol excretion was
significantly increased in mice acutely treated with SOAT2 ASO
compared to control ASO (Figure 3), it appears SOAT2
knockdown caused the liver to funnel excess hepatic cholesterol
into the feces for elimination. Since biliary cholesterol concentra-
tion was unchanged (Figure 2A), it seems likely that the surplus
hepatic cholesterol was being directed into the TICE pathway.
This conclusion is consistent with our previous study showing that
chronic SOATHKD caused a doubling of fecal neutral sterol
excretion and an elevation in the trafficking of liver-derived
cholesterol through the blood to the small intestine [21]. In the
case of both chronic and acute SOATHKD, excess hepatic
cholesterol is presumably secreted into the blood after being
packaged on nascent lipoproteins. The liver has the capacity to
Figure 3. Fecal neutral sterol excretion in mice with acute
knockdown of SOAT2 in liver. Mice were fed the high cholesterol
diet for 6 weeks and then continued on the same diet during 1 or 2
weeks of ASO treatment. Immediately following the first injection of
control ASO [C] or SOAT2 ASO [S], mice were individually housed in wire
bottom cages to collect feces for neutral sterol analysis. After 72 hours
(Day 1–3), the mice were administered a second dose of ASO and
transferred to clean wire bottom cages for a second collection of feces.
After 96 hours (Day 4–7) in this setting, the mice were fasted for
4 hours and euthanized for fluid and tissue collection. A second set of
mice received their first week of ASO doses in normal caging. After the
third ASO dose, the mice were individually housed in wire bottom
cages and feces were collected for 72 hours (Day 8–10). These mice
then received another ASO dose and were transferred to a clean wire
bottom cages in order to collect feces for 96 hrs (Day 11–14). Tissue and
fluid samples were then collected from these mice as described above.
Neutral sterol was extracted from the feces and quantitated using gas-
liquid chromatography. Data represent the means 6 SEM (n = 5–6 mice
per treatment group). Bars not sharing a common letter differ
significantly (p,0.05).
doi:10.1371/journal.pone.0098953.g003
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Figure 4. Plasma cholesterol concentration and distribution in mice with acute hepatic SOAT2 knockdown. After eating a high
cholesterol diet for 6 weeks, mice were either euthanized to collect baseline samples or were continued on diet and administered for 1 or 2 weeks
control ASO or SOAT2 ASO. Fasting plasma was isolated from 4–6 mice per treatment group and analyzed for total cholesterol (TPC) (A) and free
cholesterol (FC) (B) concentration. Data represent the means 6 SEM and bars not sharing a common letter differ significantly (p,0.05). Pooled
plasma from 4–5 mice per treatment group was separated by gel filtration chromatography (C) and fractions containing VLDL, LDL, transition
lipoproteins [TL], and HDL (D) were collected and analyzed by gas-liquid chromatography to determine the FC to TC ratio in each lipoprotein fraction.
doi:10.1371/journal.pone.0098953.g004
Figure 5. Apolipoprotein content of isolated plasma lipoproteins following acute hepatic SOAT2 knockdown. Fasting plasma was
isolated from mice treated with diet only (a), control ASO for 1 week (b), SOAT2 ASO for 1 week (c), Control ASO for 2 weeks (d), and SOAT2 ASO for 2
weeks (e). Pooled plasma was separated by gel filtration chromatography and fractions containing VLDL (A), LDL (B), transition lipoproteins [TL] (C),
and HDL (D) were collected. An equal volume within a lipoprotein fraction was loaded onto a 4–12% polyacrylamide-SDS gel. Following SDS-PAGE,
the lipoprotein fractions were immunoblotted to determine the relative abundance of apoB, apoE and apoAI.
doi:10.1371/journal.pone.0098953.g005
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create both HDL and VLDL and thus either class of lipoprotein
could be involved in moving cholesterol to the small intestine for
TICE. With acute SOATHKD, there appeared to be no change in
the protein expression of hepatic ABCA1 (Figure 6D), which is
necessary for formation of nascent HDL by the liver [35] and
consequently FC efflux. Plasma HDL-TC concentration of mice
appeared to be unchanged after 1 week and slightly reduced
following 2 weeks of SOAT2 ASO treatment (Figure 4C). The
ratio of FC to TC on plasma HDL was modestly increased with
SOATHKD but was much lower than that on other lipoprotein
classes (Figure 4D) due presumably to the ability of LCAT to
preferentially convert HDL FC to CE. Although we cannot
Figure 6. Hepatic expression of genes involved in cholesterol homeostasis in mice with acute hepatic SOAT2 knockdown. Mice were
treated as described in Figure 3 and fasting liver was collected. Quantitation of hepatic Srebf2 (A), HMG-CoA Reductase (B) and HMG-CoA Synthase
(C), SR-BI (D), ABCG5 (E), ABCG8 (F) were conducted by real-time PCR using individual RNA samples (n = 5). Data represent the means 6 SEM, and bars
not sharing a common letter differ significantly (p,0.05). Western blot analysis was used to quantify hepatic ABCA1 protein expression for individual
liver samples (G). Quantitation of hepatic TGH (H) was conducted by real-time PCR using individual RNA samples (n = 5). Western blot analysis was
used to assess hepatic TGH1 protein expression for individual liver samples (I).
doi:10.1371/journal.pone.0098953.g006
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conclude from our study whether HDL was involved in moving
hepatic cholesterol to the TICE pathway, a recent study from
Vrins et al indicated that TICE was unaltered in Abca1 deficient
mice, which have very low HDL levels [36].
With acute SOATHKD, excess hepatic cholesterol could have
also been packaged into VLDL or smaller apoB-containing
lipoproteins for delivery through the plasma to the small intestine.
This scenario is supported by our previous work that showed the
liver of mice treated chronically with SOAT2 ASO versus control
ASO secreted nascent VLDL that appeared to deliver more
cholesterol to the TICE pathway [21]. In addition, Le May et al
recently reported that TICE can be increased by eliminating
PCSK9-dependent degradation of intestinal LDLR [37]. Howev-
er, intestinal uptake of cholesterol from apoB-containing lipopro-
tein must not solely rely on LDLR since mice deficient in LDLR
have normal or increased levels of TICE [21,37]. In our current
study, plasma from acute SOATHKD mice contained VLDL,
LDL, and TL that were enriched in FC (Figure 4D) indicating the
liver was secreting a greater amount of FC on apoB-containing
lipoproteins. Treatment with SOAT2 ASO compared to control
ASO appeared to cause a reduction in both TC and apoB100
associated with VLDL (Figure 4C and 5A), which could be
interpreted as increased VLDL clearance by the small intestine. In
contrast, elevated amounts of TC and apoB100 were found in the
LDL and TL fraction of plasma from acute SOATHKD mice
(Figure 4C, 5B–C). It is possible that SOAT2 knockdown caused
the liver to produce smaller, more FC-rich LDL that feed
cholesterol into TICE. Alternatively, the accumulation of TC and
apoB100 in plasma LDL and TL could reflect reduced hepatic
LDLR expression due SOAT2 knockdown altering hepatic
cholesterol homeostasis.
Acute SOATHKD caused a substantial increase in the level of
TC and apoE found in the plasma TL fraction (Figure 4C and
5C). In addition, TL from SOATHKD mice had the highest ratio of
FC to TC (,30%) when compared to other lipoproteins classes
isolated from the plasma of mice treated with either SOAT2 ASO
or control ASO (Figure 4D). It is tempting to speculate that apoE-
rich lipoproteins act as a sink for cholesterol that is destined for the
TICE pathway. Certainly, apoE-rich TL are found to accumulate
in the plasma of LXR-agonist treated mice and Niemann-Pick C1-
like 1 hepatic transgenic mice (NPC1L1 Tg), which have been
reported to have increased TICE [28,30,37–39]. However, we
have recently discovered that NPC1L1 Tg mice deficient in apoE
have normal fecal neutral sterol excretion (Temel and Brown,
unpublished data) therefore indicating that apoE may not be
required for efficient cholesterol delivery to the TICE pathway.
Our studies of acute and chronic SOAT2 hepatic knockdown
suggest that SOAT2 inhibition can increase TICE. In addition, it
Figure 7. Intestinal expression of genes involved in cholesterol homeostasis in mice with acute hepatic SOAT2 knockdown. Mice
were treated as described in the legend for Figure 1. Quantitation of intestinal SOAT2 (A), SRBI (B), ABCG5 (C), ABCG8 (D), NPC1L1 (E) and TGH1 (F)
mRNA were conducted by real-time PCR using individual RNA samples (n = 5 per treatment group). Data represent the means 6 SEM (4–6 mice per
treatment group). Bars not sharing a common letter differ significantly (p,0.05).
doi:10.1371/journal.pone.0098953.g007
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has been shown that small molecule inhibition of SOAT2
decreases cholesterol absorption [19]. Taken together these data
suggest that inhibiting both intestinal and hepatic SOAT2 should
maximally stimulate fecal neutral sterol loss given the dual effects
of promoting TICE and limiting intestinal cholesterol re-absorp-
tion. Thus, SOAT2 inhibition could lower CVD risk by not only
decreasing the amount of pro-atherogenic cholesteryl oleate on
LDL [13,17,19,20] but also reducing the availability of cholesterol
for incorporation into LDL. Research is ongoing to create highly
selective SOAT2-specific small molecule inhibitors that could hold
promise for improved prevention and treatment of CVD in the
post-statin era.
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